- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07877727
Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network (2023-12377081)
Potenziare la Gestione Clinica Delle CMF Attraverso Una Rete Nazionale Pediatrica e Dell'Adulto Basata su Dati Biologici e Genetici / Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network
A non-profit, translational, prospective and retrospective study.
Patients will be enrolled according to the procedures described in the protocol, and samples will be processed and analyzed as specified in the protocol.
Since constitutional bone marrow failure syndromes (CMF) are rare genetic disorders characterized by a variable and incompletely defined clinical phenotype, a partially unknown genetic etiology, and pathogenetic mechanisms that are only partly understood, the investigators hypothesize that a number of patients currently diagnosed with idiopathic acquired aplastic anemia (AAA) or idiopathic single-lineage/multilineage bone marrow failure (BMF) may have been misdiagnosed and may actually have an underlying CMF.
Therefore, the investigators' primary objective is to identify CMF underlying BMF and vice versa, by defining well-characterized patient cohorts based on clinical and family history, clinical manifestations, and immunological findings; identifying disease-specific parameters and biomarkers; and providing disease-specific guidelines to facilitate early diagnosis and, consequently, enable timely and appropriate treatment.
In this context, the use of appropriate artificial intelligence (AI) tools is likely to improve the diagnostic accuracy of this approach.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Carlo Dufour
- Telefonnummer: +3901056363528
- E-post: segrematologia@gaslini.org
Studiesteder
-
-
-
Avellino, Italia
- Rekruttering
- AORN San Giuseppe Moscati Hematology and bone marrow Transplant Unit
-
Ta kontakt med:
- Antonio Maria Risitano
- Telefonnummer: +393475786759
- E-post: amrisita@unina.it
-
Genova, Italia
- Rekruttering
- IRCCS Istituto Giannina Gaslini
-
Ta kontakt med:
- Carlo Dufour
- Telefonnummer: +3901056363528
- E-post: segrematologia@gaslini.org
-
Naples, Italia
- Rekruttering
- Azienza Ospedaliera di Rilievo Nazionale Santobono Pausilipon Dipartimento di oncologia, ematologia e terapie cellulari
-
Ta kontakt med:
- Giuseppe Menna
- Telefonnummer: +393485171510
- E-post: giumenna56@libero.it
-
Verona, Italia
- Har ikke rekruttert ennå
- Università degli Studi di Verona Department of Engineering for Innovation Medicine
-
Ta kontakt med:
- Anna Savoia
- Telefonnummer: +393284695593
- E-post: Anna.savoia@univr.it
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
All patients with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH).
- Signed informed consent and/or assent obtained from the participant and/or their parents or legal guardians, as applicable.
Exclusion Criteria:
- Absence of signed informed consent and/or assent from the participant and/or their parents or legal guardians
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Fanconi anemia (FA)
Fanconi anemia (FA) |
|
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD) |
|
Congenital neutropenia (CN)
Congenital neutropenia (CN) |
|
Primary immune regulatory disorders (PIRD)
Primary immune regulatory disorders (PIRD) |
|
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia (CAMT) |
|
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Early Diagnosis and Molecular Characterization of CMF and AAA
Tidsramme: Within the 24-month project period
|
To improve the early diagnosis of constitutional bone marrow failure syndromes (CMF) and acquired aplastic anemia (AAA) through the integration of clinical, laboratory, immunological, and genetic data. At least 50 newly enrolled patients will be evaluated prospectively over the first 21 months, alongside approximately 200 previously referred patients analyzed retrospectively using artificial intelligence (AI). The diagnostic work-up will include the implementation of additional tests, such as telomere length assessment by flow-FISH, serum thrombopoietin measurement, and immunophenotyping by flow cytometry. Whole-genome sequencing and functional studies will be used to identify disease-causing variants, copy number variations (CNVs), and clarify variants of uncertain significance (VUS). Early and accurate diagnosis will support appropriate targeted treatment, genetic counseling, surveillance for bone marrow failure and malignancies, and identification of suitable related donors. |
Within the 24-month project period
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Benmargssviktforstyrrelser
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Spedbarn, nyfødte, sykdommer
- Hematologiske sykdommer
- Hudsykdommer
- Medfødte abnormiteter
- Benmargssykdommer
- Anemi, hemolytisk
- Anemi
- Hudsykdommer, genetisk
- Genetiske sykdommer, X-linked
- Hudavvik
- Myelodysplastiske syndromer
- DNA-reparasjon-mangellidelser
- Anemi, hypoplastisk, medfødt
- Anemi, aplastisk
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Ernæringsmessige og metabolske sykdommer
- Hud- og bindevevssykdommer
- Hemic og lymfatiske sykdommer
- Medfødte benmargssviktsyndromer
- Hemoglobinuri, Paroksysmal
- Fanconi anemi
- Dyseratosis Congenita
- Medfødt amegakaryocytisk trombocytopeni
- Neutropeni, alvorlig medfødt, autosomal recessiv 3
Andre studie-ID-numre
- PNRR-MR1-2023-12377081 (13958)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .